Research Industries/Vascular Technologies
This article was originally published in The Gray Sheet
Enter exclusive, worldwide marketing agreement under which Research Industries will distribute two Vascular Technologies probes that are "targeted for introduction in early fiscal 1994" (year beginning July 1). One probe "provides real-time pH and temperature in a patient's heart during bypass surgery," while the other, "by means of ultrasound, locates a patient's mammary artery to be salvaged for bypass graft material and also confirms that a new artery graft is open and functioning prior to concluding the surgery," Research Industries says.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.